Demographics (2)
- AGE - Subject age at the time of sample collection (phv00535318.v1.p1)
- SEX - Biological sex (phv00535312.v1.p1)
Disease Events (1)
- DISEASE_STATUS - Case control status of the subject for Ulcerative Colitis (UC) (phv00535317.v1.p1)
Race and Ethnicity (2)
- ETHNICITY - Self-reported ethnicity (phv00535320.v1.p1)
- RACE - Self-reported race (phv00535319.v1.p1)
Other (21)
- ANALYTE_TYPE - Analyte Type (phv00535332.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00535331.v1.p1)
- COLLECTION_METHOD - Notes on sample collection method (phv00535335.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00535311.v1.p1)
- DISEASE_DURATION_Y - Disease duration in years at the time of collection (phv00535322.v1.p1)
- DURATION_VDZ_MO - Duration of Vedolizumab therapy at the time of collection (phv00535323.v1.p1)
- GEO_ACCESSION - GEO accession ID (GSM#) (phv00535329.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00535334.v1.p1)
- IS_TUMOR - Tumor status (phv00535333.v1.p1)
- MAYO_ENDOSCOPIC_SUBSCORE - Mayo endoscopic subscore (phv00535326.v1.p1)
- MONTREAL_CLASSIFICATION - Montreal classification (phv00535325.v1.p1)
- POOLED_SUBJECT_ID - Pools containing each study subject (phv00535313.v1.p1)
- PRIOR_ANTI-TNF_EXPOSURE - Previously exposed to anti-TNF (phv00535324.v1.p1)
- RESPONDER_TO_VDZ - Responded to Vedolizumab (phv00535327.v1.p1)
- SAMPLE_ID - Sample ID (phv00535330.v1.p1)
- SAMPLE_ID - Sample ID (phv00535315.v1.p1)
- SUBJECT_ID - Subject ID (phv00535316.v1.p1)
- SUBJECT_ID - Subject ID (phv00535310.v1.p1)
- SUBJECT_ID - Subject ID (phv00535314.v1.p1)
- SUBJECT_ID - Subject ID (phv00535328.v1.p1)
- UC_MEDICATION - Medication for ulcerative colitis at the time of sample collection (phv00535321.v1.p1)